单位(元)易方达医药生物股票C(010388)利润表 |
| 报告期 |
2025/12/31 |
2025/6/30 |
2024/12/31 |
2024/6/30 |
| 收入 |
1,142,839,614 |
1,056,910,702 |
-306,626,003 |
-415,354,171 |
| 利息收入 |
1,105,469 |
559,925 |
1,138,332 |
474,472 |
| 其中：存款利息收入 |
1,105,469 |
559,925 |
1,138,332 |
474,472 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益 |
684,548,131 |
344,460,901 |
-406,022,669 |
-128,495,217 |
| 其中：股票投资收益 |
667,840,989 |
335,314,423 |
-426,354,537 |
-137,396,496 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
759,906 |
1,337 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
16,707,143 |
9,146,478 |
19,571,962 |
8,899,943 |
| 公允价值变动收益 |
445,870,322 |
706,302,898 |
96,258,558 |
-288,068,317 |
| 汇兑收益 |
- |
- |
- |
- |
| 其他收入 |
11,315,692 |
5,586,978 |
1,999,777 |
734,891 |
| 费用 |
53,206,101 |
25,866,102 |
52,340,883 |
25,346,065 |
| 管理人报酬 |
41,120,631 |
19,998,940 |
40,207,347 |
19,517,178 |
| 托管费 |
6,853,438 |
3,333,157 |
6,701,224 |
3,252,863 |
| 销售服务费 |
4,848,729 |
2,342,856 |
5,054,722 |
2,384,606 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
383,303 |
191,149 |
377,583 |
191,413 |
| 利润总额 |
1,089,633,513 |
1,031,044,600 |
-358,966,886 |
-440,700,236 |
| 减：所得税费用 |
- |
- |
- |
- |
| 净利润 |
1,089,633,513 |
1,031,044,600 |
-358,966,886 |
-440,700,236 |
*注：新浪财经提醒：以上数据由合作伙伴提供，仅供参考，交易请以正式公告数据为准。
